BEC hydrochloride (BEC HCl) is a competitive arginase inhibitor, which bind slowly. Ki of BEC HCl is 0.31 μM (pH7.5) for Arginase II, and is 0.4-0.6 μM for rat Arginase I.

Beclobrate (Sgd 24774) is a novel orally available fibric acid derivative that has shown significant lipid and cholesterol-lowering activity in rodents and may be used in the study of primary hyperlipoproteinemia.

Tat-beclin 1 acetate is a potent inducer of autophagy and interacts with the negative regulator of autophagy, GAPR-1. Tat-beclin 1 acetate decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1).

Beclin1-ATG14L Interaction Inhibitor 1 (COM 19) is a selective inhibitor targeting the specific interaction between Beclin1 and ATG14L. It impedes the formation of complex I in the lipid kinase VPS34, thus inhibiting autophagy, while leaving complex II intact, which relies on the Beclin 1-UVRAG interaction for its integrity and is essential for vesicle transport [1].

Becatecarin is a water-soluble, diethylaminoethyl analog of the antineoplastic antibiotic rebeccamycin. It intercalates into DNA, stabilizing the DNA-topoisomerase complex. This results in the potent catalytic inhibition of both topoisomerases I and II, initiating DNA cleavage and apoptosis. Becatecarin, alone or in combination with other compounds, has anti-cancer as well as myelosuppressive effects in vivo. It is also a transport substrate of the ATP-binding cassette (ABC) transporter ABCG2.

Beclamide (Chlorakon) (N-benzyl-B-chloropropionamide) is a drug that possesses anticonvulsant activity. It is no longer used. It has been used as a sedative and as an anticonvulsant. It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalized tonic-clonic seizures. It was not effective for absence seizures.

(+)-Osbeckic acid, extracted from Tartary Buckwheat, acts as a vasorelaxant and demonstrates a significant vasorelaxant effect in Sprague-Dawley rat thoracic aorta rings, with an EC50 value of 887 μM [1].

Beclin1-Bcl-2 Interaction Inhibitor 1 effectively disrupts the binding of Beclin 1 to Bcl-2, and is utilized in cancer and neurodegeneration research [1].

Tat-beclin 1, a peptide derived from the autophagy protein beclin 1, is a powerful inducer of autophagy. It interacts with GAPR-1 (GLIPR2), a negative regulator of autophagy. Tat-beclin 1 effectively reduces the buildup of polyglutamine expansion protein aggregates and inhibits the replication of various pathogens, such as HIV-1, in laboratory experiments. In addition, it has demonstrated the ability to decrease mortality in mice infected with chikungunya (CHIKV) or West Nile virus (WNV).

Quebecol is a nutraceutical agent against periodontitis.

Rebeccamycin is an antitumor antibiotic+ inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I. It also has a negligible effect on protein kinase C and topoisomerase II.

Umibecestat, also known as CNP-520, is a beta-secretase inhibitor and is a drug candidate for prevention trials in Alzheimer's disease. CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP-transgenic mice. CNP520 reduces Aβ load and neuroinflammation in APP‐transgenic mice

Elenbecestat,also known as E2609 is a BACE1 inhibitor. By inhibiting BACE, a key enzyme in the production of Aβ peptides, E2609 decreases the formation of these peptides which can aggregate into toxic oligomers and protofibrils and eventually form amyloid plaques in the brain. Elenbecestat has been shown to reduce Aβ levels in cerebrospinal fluid, was investigated in two global phase 3 studies in early AD.

Ecubectedin (PM14), a derivative within the ecteinascidins family of tetrahydroisoquinoline alkaloids, exhibits a broad spectrum of antitumor and antimicrobial properties.

Lanabecestat (AZD3293) is a highly potent and highly permeable, orally active BACE1 inhibitor (Ki: 0.4 nM) that crosses the blood-brain barrier, Lanabecestat can be used for the study of neurological diseases like Alzheimer's disease.

Umibecestat is a beta-secretase inhibitor. CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies.

Beclomethasone Dipropionate-d6 is a deuterated compound of Beclomethasone Dipropionate. Beclomethasone Dipropionate has a CAS number of 5534-09-8. Beclomethasone Dipropionate is the dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.

Becantal is a bioactive chemical.

Becampanel (AMP397) is the first competitive AMPA antagonist. Becampanel (AMP397) also is an antiepileptic agent.

Verubecestat tosylate, also known as MK-8931 or SCH 900931, is a potent and selective beta-secretase inhibitor, and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor. Verubecestat tosylate is a promising novel therapeutic drug candidate in Alzheimer's disease. Verubecestat tosylate reduced Aβ cerebral spinal fluids (CSF) levels up to 92% and was well tolerated by patients.

Siegesbeckialide I effectively suppresses LPS-induced NO production in RAW264.7 murine macrophages by directly interacting with IKKα/β.

Tat-beclin 1 TFA, a peptide originating from a segment of the autophagy protein beclin 1, effectively initiates autophagy and engages with the autophagy negative regulator, GAPR-1 (GLIPR2). It notably reduces the buildup of polyglutamine expansion protein aggregates and curtails the in vitro replication of various pathogens, including HIV-1. Moreover, Tat-beclin 1 TFA has demonstrated a reduction in mortality rates in mice infected with either chikungunya (CHIKV) or West Nile virus (WNV) [1].

Beclabuvir (BMS-791325) is a potent NS5A replication complex inhibitor that inhibits the activity of the NS5B protein expressed by HCV genotypes 1, 2, 4, and 5 and is used in the study of HCV infection.

Embeconazole (R 120758) is a triazole antifungal agent.Embeconazole has strong in vitro activity against clinically important fungi such as Candida, Aspergillus and Cryptococcus neoformans.

Trabectedin (Ecteinascidin 743) has potent antitumor activity and the potential for soft tissue sarcoma and ovarian cancer research. Trabectedin inhibits cell growth of MX-1, MCF7 and MCF7/DXR cells with IC50 values of 0.1 nM, 1.5 nM and 3.7 nM, respectively.

Verubecestat (MK-8931) (MK-8931) is an effective and specific β-secretase inhibitor and β-site APP-cleaving enzyme 1 inhibitor or BACE1 protein inhibitor.

Beclomethasone-17-Monopropionate-d3 is a deuterated compound of Beclomethasone-17-Monopropionate. Beclomethasone-17-Monopropionate has a CAS number of 5534-18-9. Beclomethasone 17-propionate is an active metabolite of Beclomethasone dipropionate and an agonist of the glucocorticoid receptor (GR). It exhibits greater affinity for GR than Beclomethasone dipropionate. Beclomethasone 17-propionate effectively suppresses cytokine production in COPD lung macrophages.

Abecomotide is a bioactive chemical.

APOBEC3G-IN-1 (MN136.0185) is a targeted APOBEC3G inhibitor with anti-HIV activity for the study of infectious diseases and cancer.

Bectumomab (IMMU-LL 2), a humanized IgG2a monoclonal antibody (mAb) against human CD22 (antigen), serves as an anti-lymphoma agent. It is utilized in imaging procedures when combined with technetium 99 (Tc99m LL2 Fab), and employed in evaluating the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL). Additionally, Bectumomab is used to examine targeting efficacy prior to radioimmunotherapy (RIT) [1].

Lanabecestat camsylate is used as a BACE1 Inhibitor.

Umibecestat is an inhibitor of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively. Umibecestat can be used for the research of alzheimer's disease.

Beclomethasone 17-propionate is an active metabolite of Beclomethasone dipropionate and an agonist of the glucocorticoid receptor (GR). It exhibits greater affinity for GR than Beclomethasone dipropionate. Beclomethasone 17-propionate effectively suppress

Beclabuvir, also known as BMS-791325, is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 at 50% inhibitory concentrations (IC50) below 28 nM. In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concentrations (EC50s) of 3 nM and 6 nM, respectively, with similar (3 to 18 nM) values for genotypes 3a, 4a, and 5a. B

Hsp90 inhibitor

Lanabecestat, also known as AZD3293 and LY3314814, is a potent, highly permeable, orally active, blood-brain barrier (BBB) penetrating, BACE1 inhibitor with unique slow off-rate kinetics. AZD3293 displayed significant dose- and time-dependent reductions in plasma, cerebrospinal fluid, and brain concentrations of Aβ40, Aβ42, and sAβPPβ.

(1α,1'S,4β)-Lanabecestat is a Beta site APP Cleaving Enzymel (BACE1) inhibitor, and has IC50s of 2.2 nM (TR-FRET assay) and 0.28 nM (sAPPp release assay), respectively.

Becocalcidiol(QRX-101, DP-006, COL-121) is a potential vitamin D analog for the treatment of psoriasis.

Alpibectir has antibacterial activity [1].

Atabecestat (JNJ-54861911) is an orally active and brain-permeable inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) that slows cognitive decline in participants with preclinical Alzheimer's disease.Atabecestat is used in the study of Alzheimer's disease.

Beclomethasone-d5 is a deuterated compound of Beclomethasone.

Beclometasone dipropionate (Vancenase) is the dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.

Elenbecestat (E2609) is an effective oral bioutilization and CNS penetrating ACE-1 inhibitor for the treatment of Alzheimer's disease.

Becotatug (JMT-101) is an IgG1 antibody that targets EGFR and can be conjugated to Afatinib and Osimertinib, functioning as a synthetic antibody-drug conjugate (ADC) [1].

Beclometasone dipropionate monohydrate is a precursor drug to Beclometasone, an orally active glucocorticoid receptor agonist that agonizes the glucocorticoid receptor and inhibits inflammation and hyperproliferation. monohydrate can be used to study asthma.

Libecillide is a bioactive chemical.

Verubecestat TFA, also known as MK-8931 or SCH 900931, is a potent and selective beta-secretase inhibitor, and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor. Verubecestat TFA is a promising novel therapeutic drug candidate in Alzheimer's disease. Verubecestat TFA reduced Aβ cerebral spinal fluids (CSF) levels up to 92% and was well tolerated by patients.

Vibecotamab (XmAb14045) is a potent bispecific antibody targeting CD123 and CD3, promoting T cell-mediated elimination of cells expressing CD123. It exhibits antitumor properties and is applicable in studies on acute myeloid leukemia [1].

SB-334867 free base (SB334867A free base) is a selective orexin-1 (OX1) receptor antagonist.